Alteogen said on the 26th that it completed a Patent Cooperation Treaty (PCT) filing for its technology to develop a subcutaneous injection formulation of antibody-drug conjugate (ADC) medicines.
An ADC is a therapy that attaches a drug (payload) to an antibody that binds to cancer cells to deliver it precisely to the cancer cells. Because it targets only cancer cells accurately, it is called a guided missile.
The company filed a patent for technology that can convert intravenously administered ADC medicines into a subcutaneous injection formulation by using its human hyaluronidase platform technology "ALT-B4."
A PCT filing is an international patent application system that allows applicants to seek patents in multiple countries with a single application. If an applicant submits a PCT international application to its national patent office, it has the same effect as filing separately in about 150 designated countries.
Park Soon-jae, chief executive officer of Alteogen, said, "For ADC medicines administered intravenously, it is important to control the infusion rate to avoid raising blood concentrations that can cause toxicity issues," adding, "If we convert ADCs to subcutaneous injections using ALT-B4, they can be administered conveniently and quickly, and the blood concentration of the ADC will rise gradually, which can reduce side effects caused by the toxic compounds conjugated to the ADC."